anastrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   123 Trials   123 Trials   2738 News 


«12...1920212223242526272829...4142»
  • ||||||||||  Arimidex (anastrozole) / AstraZeneca, Remedica
    [VIRTUAL] An audit of chemoprevention provision in a breast cancer family history clinic (e-poster) -  Aug 14, 2020 - Abstract #EBCCI2020EBCC-I_719;    
    The audit also demonstrated a higher level of uptake of chemoprevention than previously reported nationally. Findings suggest more time should be allowed for answering questions and offering guidance on potential side effects and how they can be managed.
  • ||||||||||  Arimidex (anastrozole) / AstraZeneca, Remedica
    [VIRTUAL] An audit of chemoprevention provision in a breast cancer family history clinic (e-poster) -  Aug 14, 2020 - Abstract #EBCCI2020EBCC-I_399;    
    The audit also demonstrated a higher level of uptake of chemoprevention than previously reported nationally. Findings suggest more time should be allowed for answering questions and offering guidance on potential side effects and how they can be managed.
  • ||||||||||  goserelin acetate / Generic mfg., anastrozole / Generic mfg.
    Phase classification, Enrollment change, Trial termination:  Influence of Aromatase Inhibitors and GnRH Analogs to Treat Uterine Leiomyoma by Vaginal Hysterectomy (clinicaltrials.gov) -  Aug 13, 2020   
    P=N/A,  N=5, Terminated, 
    Findings suggest more time should be allowed for answering questions and offering guidance on potential side effects and how they can be managed. Phase classification: P3 --> P=N/A | N=50 --> 5 | Recruiting --> Terminated; No grant was received then we stopped the recruitment
  • ||||||||||  anastrozole / Generic mfg.
    Enrollment open:  PHANTOM: Pulmonary Hypertension and Anastrozole Trial (clinicaltrials.gov) -  Aug 8, 2020   
    P2,  N=84, Recruiting, 
    Active, not recruiting --> Completed Active, not recruiting --> Recruiting
  • ||||||||||  camizestrant (AZD9833) / AstraZeneca
    Trial primary completion date:  SERENA-1: Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer. (clinicaltrials.gov) -  Jul 23, 2020   
    P1,  N=182, Recruiting, 
    However, our results suggest that weekly oral risedronate is unable to completely prevent anastrozole induced bone loss at the hip. Trial primary completion date: Mar 2021 --> Jan 2022
  • ||||||||||  letrozole / Generic mfg., Arimidex (anastrozole) / AstraZeneca, Remedica, tamoxifen / Generic mfg.
    [VIRTUAL] Lipid changes during endocrine therapy in breast cancer patients: The results of a 5-year real-world retrospective analysis (On-Demand) -  Jul 21, 2020 - Abstract #ESMO2020ESMO_527;    
    Results For premenopausal BC patients, LDL levels rapidly decreased at 1 year in the tamoxifene (TAM) group compared with baseline (p<0.05), and the decline remained for the following 4 years...For postmenopausal BC patients, there was no statistical difference in the lipid profiles (TG, TC, LDL and HDL) in letrozole (LET), anastrozole (ANA) and exemestane (EXE) group compared with the control group, respectively...Legal entity responsible for the study: West China School of Medicine/West China Hospital, Sichuan University. Funding: Has not received any funding.
  • ||||||||||  Arimidex (anastrozole) / AstraZeneca, Remedica
    Journal:  Optimized Polyethylene Glycolylated Polymer-Lipid Hybrid Nanoparticles as a Potential Breast Cancer Treatment. (Pubmed Central) -  Jul 19, 2020   
    Recruiting --> Active, not recruiting | Trial completion date: Jul 2021 --> Jul 2022 | Trial primary completion date: Jul 2020 --> Jul 2021 PEGylated polymeric nanoparticles presented a stable encapsulated system with which to incorporate an anticancer drug (ANS) with a high percentage of entrapment efficiency (around 80%), good size uniformity, and induction of apoptosis in MCF-7 cells.
  • ||||||||||  Phase classification, Enrollment change, Trial completion date, Trial primary completion date:  EUROPA: ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged ?70 Years Early Stage Breast Cancer (clinicaltrials.gov) -  Jul 14, 2020   
    P3,  N=926, Not yet recruiting, 
    Trial completion date: Jun 2022 --> Jan 2023 | Trial primary completion date: Jan 2022 --> Aug 2022 Phase classification: P2/3 --> P3 | N=600 --> 926 | Trial completion date: Mar 2026 --> Dec 2025 | Trial primary completion date: Mar 2023 --> Dec 2025
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Trial completion date, Trial primary completion date:  PREDIX LumB: Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases (clinicaltrials.gov) -  Jul 7, 2020   
    P2,  N=180, Recruiting, 
    Since the addition of CDKI to endocrine therapy seemed to benefit all clinicopathological subgroups of interest in this pooled analysis, further research is needed to identify patient subgroups for whom endocrine therapy alone might be appropriate for first-line or second-line treatment of hormone receptor-positive, HER2-negative metastatic breast cancer. Trial completion date: Jun 2024 --> Jun 2031 | Trial primary completion date: Jun 2018 --> Dec 2021
  • ||||||||||  [VIRTUAL] More Than Meets the Eye: Bronchopulmonary Leukemic Infiltrates in Chronic Lymphocytic Leukemia (ATS 2020 Virtual) -  Jul 6, 2020 - Abstract #ATSI2020ATS-I_6255;    
    He has a history of chronic lymphocytic leukemia (CLL) complicated by hypogammaglobulinemia on intravenous immunoglobulin, localized melanoma status post excision, and left breast carcinoma status post mastectomy, radiation therapy, and adjuvant anastrazole...After six weeks of treatment with voriconazole, his fevers persisted and CT of the chest demonstrated progressive patchy ground-glass opacities and nodular consolidation...Time limited CLL specific therapy with obinutuzumab/chlorambucil was initiated...It is important to differentiate a possible "passenger effect", which is a reactive, nonspecific recruitment of inflammatory cells into the lung parenchyma. An appropriate level of suspicion and a proper diagnosis can lead to discontinuation of antimicrobial therapy and initiation of CLL directed therapy.
  • ||||||||||  Arimidex (anastrozole) / AstraZeneca, Remedica, tamoxifen / Generic mfg.
    [VIRTUAL] A Rare Cause of Cystic Lung Disease (ATS 2020 Virtual) -  Jul 6, 2020 - Abstract #ATSI2020ATS-I_2810;    
    There are no guidelines for treatment. However, the presence of estrogen/progesterone receptors allow for hormonal agents like selective estrogen receptor modulators (Tamoxifen), aromatase inhibitors (Anastrazole) and gonadotropin releasing hormone agonists (Leuprolide) to be used as potential agents in symptomatic patients.
  • ||||||||||  anastrozole / Generic mfg.
    Enrollment closed, Trial completion date, Trial primary completion date:  Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women (clinicaltrials.gov) -  Jul 2, 2020   
    P2,  N=42, Active, not recruiting, 
    However, the presence of estrogen/progesterone receptors allow for hormonal agents like selective estrogen receptor modulators (Tamoxifen), aromatase inhibitors (Anastrazole) and gonadotropin releasing hormone agonists (Leuprolide) to be used as potential agents in symptomatic patients. Trial completion date: Dec 2018 --> Aug 2020 | Trial primary completion date: Dec 2018 --> Aug 2020 | Completed --> Active, not recruiting
  • ||||||||||  letrozole / Generic mfg., Arimidex (anastrozole) / AstraZeneca, Remedica, exemestane / Generic mfg.
    Review, Journal:  Polyphenolic natural products and natural product-inspired steroidal mimics as aromatase inhibitors. (Pubmed Central) -  Jun 29, 2020   
    Pursuit of this strategy over the last few decades has been largely successful although complications and challenges remain. This review highlights the aromatase activity of natural stilbenes, chalcones, and flavanones and synthetically inspired versions thereof and draws attention to new and under-investigated areas within each class worthy of pursuit.
  • ||||||||||  Opdivo (nivolumab) / BMS
    Trial completion date, Trial primary completion date:  CheckMate 7A8: A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer (clinicaltrials.gov) -  Jun 25, 2020   
    P2,  N=136, Recruiting, 
    Our data support treatment guideline recommendations involving the new combinations of hormone therapies plus targeted therapies as first-line or second-line treatments, or in both settings, in women with hormone-receptor-positive, HER2-negative metastatic breast cancer. Trial completion date: Nov 2021 --> Mar 2022 | Trial primary completion date: Oct 2021 --> Mar 2022
  • ||||||||||  Arimidex (anastrozole) / AstraZeneca, Remedica
    [VIRTUAL] Case Report: Killian-Jamieson Diverticulum Presenting as a Thyroid Nodule () -  Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_2169;    
    While literature exists documenting the etiology, pathogenesis, and medical/surgical treatments for KJDs, only a few case reports exist reporting the resemblance KJDs have with thyroid nodules. This case report hopes to illustrate non-endocrinology pathologies that can mimic thyroid nodules while encouraging current healthcare practitioners to recognize the existence of these conditions so that wasteful diagnostic tests or invasive procedures can be avoided.
  • ||||||||||  Arimidex (anastrozole) / AstraZeneca, Remedica, bicalutamide / Generic mfg.
    [VIRTUAL] A Case of Familial Male-Limited Precocious Puberty With a Novel Mutation () -  Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_1646;    
    This implies that the addition of the anastrozole to an LHRHa apart from being safe, is effective in ameliorating substantially Near Adult Height making the intervention meaningful. We report a novel mutation in the LHCGR gene causing FMPP in a 6-month-old male who is responding very well to a combination of bicalutamide and anastrazole with marked decrease in growth velocity, pubertal progression and skeletal advancement.
  • ||||||||||  [VIRTUAL] Anthropometric and Reproductive Outcomes of Patients with Gonadotropin-Independent Precocious Puberty Due to McCune-Albright Syndrome After Treatment with Distinct Therapeutic Agents () -  Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_1604;    
    All patients were treated with one or more of the following agents: tamoxifen, medroxyprogesterone acetate, aromatase inhibitors (anastrozole or letrozole) and anti-androgens (cyproterone), and, in cases with secondary gonadotropic axis activation, depot GnRHa was used...Tamoxifen plus medroxyprogesterone, or cyproterone, or leuprorelin were used (each one) as the first choice in 1 patient (7.6%)...Despite a reasonable number of treatment options for peripheral PP in MAS, none of them showed proven effective results in stopping vaginal bleeding, reduce pubertal progression and preserving potential genetic adult height. Therefore, due to the extremely heterogeneous nature of PPP of MAS, the clinical treatment remains a challenge.
  • ||||||||||  Arimidex (anastrozole) / AstraZeneca, Remedica, Faslodex (fulvestrant) / AstraZeneca
    Journal:  Fulvestrant plus anastrozole for metastatic breast cancer. (Pubmed Central) -  Jun 18, 2020   
    Due to the aggressive nature of the tumor and quick development of metastasis, early diagnosis gives the best chance of resection and hence the greatest chances of survival. No abstract available